Seromex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Seromex

Quick Facts

Property Description
Active Ingredient Fluoxetine (Fluoxetine Hydrochloride)
Form Capsules, Tablets, Oral Solution
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
Common Use Supporting mood and emotional stability
Origin Synthetic compound

What Type of Medicine is Seromex?

Seromex is a prescription-only medication whose active ingredient is the synthetic compound fluoxetine. It is primarily classified as an antidepressant and belongs to the class of Selective Serotonin Reuptake Inhibitors (SSRIs). This classification is clinically recognized.

Seromex is provided as a single-ingredient, orally administered product. The availability of both solid dosage forms (capsules, tablets) and a liquid oral solution is a distinguishing feature, offering flexibility for patients who require tailored administration. The therapeutic approach is focused on systemic action to modulate neurochemistry.

Composition, Forms, and General Purpose

Seromex is supplied in various dosage forms for oral administration, all containing the active substance fluoxetine. The medication's general purpose is to promote the long-term maintenance of stability in mood and emotional regulation by addressing underlying chemical imbalances.

Seromex functions by selectively blocking the reuptake of the neurotransmitter serotonin in the brain. This key action increases the concentration of available serotonin in the synaptic space. This ultimately helps stabilize the nerve cell communications that govern mood and emotional response, encouraging a return to a more balanced mental state for individuals experiencing psychological distress.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH National Library of Medicine

What side effects are possible with Seromex?

Possible Side Effects and Safety Information

The safety profile of Seromex (fluoxetine) is organized by regulatory agencies using frequency-based classifications and system-organ classes. This ensures a standardized description of potential risks observed during clinical use and post-marketing experience.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to incidence rates documented in official regulatory sources:

Classification Common Examples (from official labeling)
Very Common (ge 10%) Headache, Insomnia, Nausea, Diarrhea
Common (ge 1% - <10%) Dizziness, Tremor, Anxiety, Anorexia, Dry mouth, Sweating, Decreased libido
Uncommon/Rare Seizures, Hyponatremia, Serious skin reactions, QT Prolongation, Serotonin Syndrome

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile highlights several serious adverse reactions that warrant specific observation. These include an increased risk of Suicidal Thoughts and Behaviors in children, adolescents, and young adults, which is a key documented safety warning. Other rare but serious documented risks include the potential for Serotonin Syndrome or NMS-like reactions, and cardiovascular risks such as QT Prolongation and ventricular arrhythmia.

Safety notes for specific populations exist, including that older adults may be more susceptible to Hyponatremia (low sodium levels), and that patients with hepatic impairment may require less frequent administration. The possibility of Activation of Mania or Hypomania is also a documented safety constraint.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents detail the potential manifestations and required emergency response actions for Seromex (fluoxetine) overdosage.

Documented Overdose Manifestations

Overdosage may present with effects primarily involving the Central Nervous System, Cardiovascular System, and Gastrointestinal System. Common documented presentations include CNS effects such as somnolence, agitation, and tremor, alongside gastrointestinal effects like nausea and vomiting, and rapid heartbeat (tachycardia).

Severe Outcomes and Mandated Actions

Regulatory labeling highlights the potential for severe or life-threatening outcomes, including seizures, coma, and Serotonin Syndrome (a specific, severe reaction). Serious cardiac risks, such as QT prolongation and ventricular arrhythmia (including Torsades de Pointes), are also documented. Individuals must seek immediate medical attention for any suspected overdose. Emergency services should be contacted immediately if the affected person collapses or experiences a seizure, according to government guidance.

Monitoring and Management

The regulatory information states that no specific antidote is known. Management focuses solely on symptomatic and supportive treatment. Due to the documented cardiac risks and the drug's long elimination half-life, ECG monitoring and extended clinical observation are required as part of the official management procedure.

Therapeutic Uses of Seromex

What Seromex Treats: Main Uses and Benefits

Seromex (fluoxetine) is commonly used to help with conditions characterized by periods of heightened symptoms, such as Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, Panic Disorder, and Premenstrual Dysphoric Disorder (PMDD). The medication is relevant for easing symptoms that create noticeable physiological strain, including sustained low mood, intrusive thoughts, and unexpected surges of fear. It is also used in cases where depression has been treatment-resistant to prior management.

This supportive management contributes to maintaining functional stability. Seromex helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases. It is often applied during phases of increased distress or discomfort, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Symptom Support
Mood/Affective Helps address symptoms that create noticeable physiological strain.
Compulsive/Impulsive Supports management of symptoms that interfere with daily functioning.
Episodic Tension Is relevant for easing symptoms associated with acute or episodic changes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Seromex?

Seromex (fluoxetine) eligibility is strictly defined by regulatory documents, establishing absolute prohibitions and specific age and comorbidity restrictions.

Absolute Contraindications (Must Not Use)

Use of Seromex is contraindicated and strictly prohibited for individuals who have a known hypersensitivity to fluoxetine or any of its ingredients. It must not be used by patients who are currently taking a Monoamine Oxidase Inhibitor (MAOI), or who have discontinued an MAOI intended for psychiatric disorders within the last 14 days, due to the risk of serious reactions. Concurrent use with agents such as pimozide or thioridazine is also prohibited.


Eligibility and Restricted Use

Population Group Regulatory Status
Adults (18+ years) Approved for labeled indications.
Pediatric (Under 7/8 years) Safety and effectiveness not established.
Hepatic Impairment Use requires a lower or less frequent dosage.
Pregnancy Use is conditional; requires potential benefit to outweigh risk.
Lactation Not recommended by regulatory labeling.

Use requires caution in the geriatric population and in patients with a history of seizures or risk factors for QT prolongation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Seromex (fluoxetine) is structured around two primary classes of risk: pharmacokinetic interactions and pharmacodynamic interactions. The most critical restrictions involve contraindicated combinations and mandatory timing requirements.

Contraindications and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, is strictly prohibited. The use of Pimozide and Thioridazine is also contraindicated due to the risk of QT prolongation and altered plasma levels. Due to the long elimination half-life, a mandatory 5-week washout period must elapse after discontinuing Seromex before starting a psychiatric MAOI.

Metabolic and Pharmacodynamic Effects

Seromex is officially described as a potent inhibitor of the CYP2D6 enzyme pathway. This pharmacokinetic effect can cause increased plasma concentrations of co-administered drugs metabolized by this enzyme, such as certain Tricyclic Antidepressants and antiarrhythmics like Propafenone and Flecainide. A significant pharmacodynamic risk involves the co-use of other serotonergic agents (e.g., Triptans, Tramadol), which elevates the potential for Serotonin Syndrome. Furthermore, co-use with drugs that interfere with hemostasis, such as NSAIDs and Warfarin, may potentiate the risk of abnormal bleeding.

Mechanism of Action

Seromex, a pharmaceutical agent containing fluoxetine, functions as a selective serotonin reuptake inhibitor (SSRI). Its primary biological target is the serotonin transporter (SERT) protein located on the presynaptic neuronal membrane in the central nervous system. Seromex acts as an inhibitor, specifically blocking the reuptake of the neurotransmitter 5-hydroxytryptamine (5-HT, serotonin) from the synaptic cleft back into the presynaptic neuron. This blockade mechanistically increases the extracellular concentration of 5-HT, prolonging its residence time and enhancing the magnitude of postsynaptic receptor activation.

Downstream, the sustained increase in synaptic 5-HT concentration triggers complex adaptive changes in the serotonin receptor system, including the delayed downregulation of somatodendritic 5-HT1A autoreceptors. Additionally, fluoxetine exhibits secondary, mild antagonist activity at 5-HT2C receptors. The collective consequences of these molecular interactions, particularly the increased synaptic serotonergic signaling, result in systemic neuromodulation within various neural circuits.

Dosage and Administration Information

How to Use Seromex

Seromex is administered orally and is available in multiple formulations, including immediate-release capsules, tablets, a liquid solution, and a 90 mg delayed-release (DR) capsule for weekly use.

Administration Principles

Feature Official Usage Guideline
Route of Administration Oral (by mouth) for all approved formulations.
Timing in Relation to Meals Can be administered with or without food.
Preparation Requirements The oral solution must be shaken well before use and measured with a marked device for accuracy.

Official Dosing and Frequency

The standard adult initial dose for Major Depressive Disorder and Obsessive-Compulsive Disorder is typically 20 mg once daily, generally taken in the morning. For indications like Bulimia Nervosa, the established daily dose is fixed at 60 mg. Daily doses above 20 mg may be taken in divided doses (e.g., morning and noon). The maximum daily dose for immediate-release forms is 80 mg for most uses. The 90 mg DR capsule is taken once per week and should be initiated seven days after the last 20 mg daily dose.

Usage Protocol Over Time

Dose adjustments are generally considered after several weeks (3–4 weeks) if insufficient response is observed, reflecting the time required to assess stability. Treatment for Major Depressive Disorder is typically continued for at least 6 months to ensure stabilization. A lower or less frequent dose (e.g., 20 mg every other day) is advised for patients with hepatic impairment. Pediatric patients (age 7 or 8 years, depending on authorized use) typically begin with a lower 10 mg daily dose. If a daily dose is missed, the official direction is to skip the missed dose and resume the normal schedule, avoiding doubling the next intake.

Recent Clinical Evidence

Research evidence / Overview of studies for Seromex

Seromex (fluoxetine) was studied for several conditions. The evidence available to regulators is drawn primarily from short-term, placebo-controlled Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. This research provides context about the types of changes observed in study populations and highlights areas where long-term effects are not fully established.


Evidence Base for Major Depressive Disorder (MDD)

The evidence base for conditions characterized by functional limitations, such as MDD, is extensive. Research examined Seromex through numerous short-term (8 to 12-week) RCTs where adult participants was studied for outcomes related to systemic or functional imbalance, such as changes in standardized depressive symptom scores. Findings describe patterns where changes in depressive symptom scores were observed in the study populations. However, regulatory reviews and large-scale summaries data show patterns related to the measured difference between Seromex and the placebo group was limited in size in some adult studies. Furthermore, follow-up durations were limited in the acute trials.

Evidence Base for Obsessive-Compulsive Disorder (OCD) and Panic Disorder

Seromex was evaluated in settings focusing on conditions characterized by episodic or acute changes, such as OCD and Panic Disorder. For OCD, research examined symptoms in short-term placebo-controlled RCTs using specific measurement tools. For Panic Disorder, research explored changes in outcomes related to episodic or acute changes, such as the frequency of full panic attacks. Data are still emerging regarding the durability of these measured outcomes when treatment was observed in patients for periods longer than one year.


Evidence Base for Bulimia Nervosa and Premenstrual Dysphoric Disorder (PMDD)

For Bulimia Nervosa, research included both short-term RCTs that examined the recorded number of weekly binge-eating episodes and purging episodes. Longer-term maintenance studies were evaluated in patients to assess the prevention of symptom return. For PMDD, the research was evaluated in adult women presenting with cycles of stability and flare-ups. The trials explored outcomes related to fluctuating or unstable symptoms by comparing two different study schedules.

Gaps in Knowledge and Areas of Research Uncertainty

The research landscape is extensive, but evidence highlights what is known — and what is still uncertain. Key limitations documented in the regulatory record include: Subgroup findings are uncertain or insufficient for many complex patient groups, such as older adults with multiple medical conditions. Additionally, there is limited information for long-term outcomes regarding the sustained impact on daily functioning beyond the one-year mark across most indications.

Key Studies & References

  1. Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis (Covers BN outcomes and dropout rates)

Frequently Asked Questions (FAQ)

Common questions about Seromex (FAQ)

Q: Do people feel tired or drowsy when taking Seromex?

A: Official labeling lists dizziness and somnolence (drowsiness) among the adverse reactions associated with treatment. Furthermore, regulatory documents state that the medication has the potential to impair judgment, thinking, and motor skills. This potential may be considered when performing tasks that require concentration.


Q: Is Seromex safe to use for people who have kidney issues?

A: Regulatory information advises caution for patients with severe renal impairment, which refers to severe kidney problems. While Seromex is primarily metabolized by the liver, official guidance indicates that a lower or less frequent dose may be necessary for these individuals.


Q: What happens if Seromex is stopped suddenly?

A: Stopping the treatment abruptly may cause discontinuation symptoms, such as dizziness, sensory disturbances, insomnia, and tremor. Official regulatory advice recommends that discontinuation be accomplished by gradually reducing the dose over a period of at least one to two weeks.


Q: Are there any required tests or monitoring while taking Seromex?

A: For patients with risk factors for QT prolongation (a change in the heart's electrical rhythm) and ventricular arrhythmia (an irregular heartbeat), ECG assessment (an electrocardiogram) and periodic ECG monitoring should be considered when starting treatment.


Q: What should I tell my dentist or surgeon before a procedure if I am taking Seromex?

A: Official safety constraints state that Seromex can increase the risk of abnormal bleeding. Regulatory constraints indicate that a surgeon or dentist be informed, especially if procedures involve the use of other medications that affect blood coagulation (blood clotting), such as certain pain relievers.


Q: Can Seromex make other medications I take less effective?

A: Yes, official regulatory documents indicate that Seromex has the potential to make certain opioid pain medications, such as codeine and tramadol, less effective. This occurs because Seromex may interfere with the enzyme needed to convert these specific pain relievers into their active forms.


Q: Is there any official information about Seromex and driving or operating machinery?

A: Yes, regulatory documents clearly state that Seromex has the potential to impair judgment, thinking, and motor skills. Regulatory information advises that individuals consider the potential for impairment before operating hazardous machinery, including driving.


Q: Do official patient information leaflets describe any potential vision changes with Seromex?

A: Yes, the official label includes a warning about the risk of angle-closure glaucoma, which is a condition that increases pressure in the eye. This risk may be accompanied by symptoms like eye pain, changes in vision, or swelling in the area of the eye.


Q: What happens if Seromex is taken with alcohol?

A: Official product information suggests avoiding the consumption of alcohol during treatment with Seromex. This is because alcohol may increase the risk or severity of nervous system side effects, such as dizziness, drowsiness, and impaired judgment.


Q: Does Seromex contain any known common allergens like lactose or gluten?

A: Official labeling lists the full range of excipients (inactive ingredients) used in each dosage form. Reviewing this list is described as necessary to identify any known allergens.


Q: Are there any specific warning signs that mean I should call a doctor while on Seromex?

A: Official safety warnings describe the importance of recognizing signs of serious reactions. These include the emergence or worsening of depression, the appearance of suicidal thoughts, symptoms of Serotonin Syndrome (like agitation, fever, or hallucinations), or severe allergic reactions such as rash or swelling.


Q: Does Seromex have any known impact on fertility?

A: Nonclinical studies, which are those conducted on animals, have shown that the active ingredient fluoxetine impaired fertility in male rats. Regulatory documents note that the potential risk this poses for human fertility is unknown.


Q: How does Seromex affect blood pressure?

A: The label indicates that caution may be necessary for patients with uncompensated heart failure. Post-marketing reports have noted cases of hypotension (low blood pressure) and orthostatic hypotension, which is a drop in blood pressure that happens when standing up.


Q: Can Seromex be split, crushed, or chewed?

A: The delayed-release capsules must be swallowed whole and not cut, crushed, or chewed to avoid altering the intended release of the medicine. No general instruction is given in official sources for altering the standard capsules or tablets.


Q: Is it generally described as safe to stop Seromex gradually?

A: Yes, official regulatory guidance describes that discontinuation of the medicine should involve a gradual dose reduction over a period of at least one to two weeks. This tapering process is intended to minimize the risk of experiencing discontinuation symptoms.

How should Seromex be stored and disposed of?

How to Store and Dispose of Seromex

The storage and disposal of Seromex (fluoxetine) must strictly adhere to the conditions mandated in the official regulatory labeling to ensure product integrity.

Storage Requirements

Seromex should be stored at Controlled Room Temperature, typically maintained between 20 C to 25 C (68 F to 77 F). Do not store the medicine above 25 C. The oral solution must be kept in a tightly closed container and must be discarded 60 days after first opening, regardless of the expiration date. It is a mandatory requirement that the medicine be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Seromex must be disposed of according to local regulations and pharmacy instructions. Do not dispose of the medicine via household waste or by flushing it down the toilet or drain, as proper disposal is necessary to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Seromex found in:

A-Z Index: